* Adaptive Biotechnologies Corp ADPT.OQ reported a
quarterly
adjusted loss of 30 cents per share for the quarter ended in
December, lower than the same quarter last year, when the
company reported EPS of -28 cents. The mean expectation of
eight analysts for the quarter was for a loss of 33 cents per
share. Wall Street expected results to range from -36 cents
to -30 cents per share.
* Revenue fell 17.1% to $45.78 million from a year ago;
analysts
expected $48.46 million.
* Adaptive Biotechnologies Corp's reported EPS for the
quarter was
a loss of 48 cents.
* The company reported a quarterly loss of $69.44 million.
* Adaptive Biotechnologies Corp shares had fallen by 26.1%
this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 19.9%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Adaptive
Biotechnologies Corp is $8.50
This summary was machine generated from LSEG data February 14 at
11:15 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.33 -0.30 Beat
Sep. 30 2023 -0.34 -0.35 Missed
Jun. 30 2023 -0.35 -0.33 Beat
Mar. 31 2023 -0.38 -0.40 Missed